Study Gene Expression (Cdkn1a and Tgfb1) of the Effect of Nano-Genistein on Rats Induced with Lead

Safa Masser Kmosh; Raghda S.M.  Al-Omari; Huda Noor  Hasan

doi:10.51699/cajmns.v7i2.3110

Authors

Safa Masser Kmosh AL-Furat AL - Awsat Technical University, Al – Qadisiyah Polytechnic College, Iraq
Raghda S.M. Al-Omari AL-Furat AL - Awsat Technical University, Al – Qadisiyah Polytechnic College, Iraq
Huda Noor Hasan AL-Furat AL - Awsat Technical University, Al – Qadisiyah Polytechnic College, Iraq

DOI:

https://doi.org/10.51699/cajmns.v7i2.3110

Keywords:

Lead, Gene Expression, Nano, Genistein

Abstract

The Lead (Pb) exposure is a significant environmental health issue, exerting extensive adverse effects on several physiological systems. This study examined the preventive effects of nano-genistein, a soy-derived isoflavone, against lead-induced poisoning in male rats. The control group (C) had a mean body weight of 185.42 ± 2.141 grams. The Lead (Pb) group (T1), which received lead acetate (30 mg/kg body weight, orally), had a significantly reduced mean body weight of 141.21 ± 3.210 grams (p < 0.05). The Nano-genistein group (T2), which received nano-genistein (10 mg/kg body weight, intraperitoneally), had a significantly increased mean body weight of 242.11 ± 6.045 grams (p < 0.05) compared to the control group. The Pb + Nano-genistein group (T3), which received lead acetate and nano-genistein, had a mean body weight of 201.41 ± 4.665 grams, significantly higher than the Lead (Pb) group (T1, p < 0.05), however lower than the Nano-genistein group (T2, p < 0.05). Exposure to lead (Pb) in the Pb group (T1) significantly increased the expression levels of the Cdkn1a and Tgfb1 (TGFβ1) genes to 9.754 ± 0.210 and 7.954 ± 0.710, respectively (p < 0.05), in comparison to the control group. The administration of nano-genistein in the Nano-genistein group (T2) resulted in a significant decrease in Cdkn1a and Tgfb1 (TGFβ1) expression levels to 0.721 ± 0.172 and 0.504 ± 0.272, respectively (p < 0.05). In the Pb + Nano-genistein group (T3), the combination of lead exposure and nano-genistein treatment led to Cdkn1a and Tgfb1 (TGFβ1) expression levels of 3.214 ± 0.101 and 2.874 ± 0.141, respectively, which were significantly higher than those in the control group (p < 0.05), yet substantially lower than those in the Lead (Pb) group (T1, p < 0.05). The results demonstrate that lead exposure significantly reduced body weights and increased the expression of Cdkn1a and Tgfb1 (TGFβ1) genes in male rats, while nano-genistein therapy had a protective effect, mitigating these detrimental consequences. The combination of lead and nano-genistein partially reduced the harmful effects of lead, indicating that nano-genistein may possess therapeutic potential in mitigating lead-induced toxicity. The research offers significant insights into the protective function of nano-genistein against lead exposure and necessitates more exploration in preclinical and clinical environments. words.

References

D. C. Bellinger, J. Burger, T. J. Cade, D. A. Cory-Slechta, M. Finkelstein, H. Hu, and B. P. Lanphear, “Low-level lead exposure and cognitive function in children and adults: A review of epidemiological evidence,” Environ. Health, vol. 23, no. 1, p. 15, 2024, doi: 10.1186/s12940-024-00866-4.

M. Desrochers-Couture, Y. Oulhote, T. E. Arbuckle, W. D. Fraser, J. R. Séguin, E. Ouellet, and G. Muckle, “Prenatal, concurrent, and sex-specific associations between blood lead concentrations and IQ in preschool Canadian children,” Environ. Int., vol. 158, p. 106933, 2022, doi: 10.1016/j.envint.2021.106933.

T. Vorvolakos, S. Arseniou, and M. Samakouri, “There is no safe threshold for lead exposure: A literature review,” Psychiatriki, vol. 27, no. 3, pp. 204–214, 2022, doi: 10.22365/jpsych.2022.2703.204.

A. R. Zota, A. M. Riederer, A. S. Ettinger, L. A. Schaider, J. P. Shine, C. J. Amarasiriwardena, and M. G. Weisskopf, “Associations between metals in residential drinking water and pulse pressure: A cross-sectional study in the Multi-Ethnic Study of Atherosclerosis,” Environ. Health, vol. 21, no. 1, pp. 1–13, 2022, doi: 10.1186/s12940-022-00842-9.

J. Briffa, E. Sinagra, and R. Blundell, “Heavy metal pollution in the environment and their toxicological effects on humans,” Heliyon, vol. 7, no. 9, p. e04691, 2021, doi: 10.1016/j.heliyon.2021.e04691.

E. Obeng-Gyasi, J. Roostaei, and J. M. Gibson, “Lead in drinking water: A survey of exposure biomarkers and cognitive effects in a US cohort,” Int. J. Environ. Res. Public Health, vol. 19, no. 4, p. 2089, 2022, doi: 10.3390/ijerph19042089.

D. Thavarajah, P. Thavarajah, A. Abare, S. Basnagala, C. Lacher, P. Smith, and G. F. Combs Jr., “Pulses: A mineral- and nutrient-dense complement to plant-based diets,” Nutrients, vol. 14, no. 2, p. 374, 2022, doi: 10.3390/nu14020374.

M. Messina, S. Blanco Mejia, A. Cassidy, A. Duncan, M. Kurzer, C. Nagato, et al., “Neither soyfoods nor isoflavones warrant classification as endocrine disruptors: A technical review of the observational and clinical data,” Crit. Rev. Food Sci. Nutr., vol. 61, no. 6, pp. 1021–1075, 2021, doi: 10.1080/10408398.2020.1718845.

S. Qiu, Z. Jiang, Z. Huang, X. Chen, X. Qian, Q. Gao, and H. Wang, “Genistein attenuates oxidative stress and inflammatory response in chondrocytes via activation of Nrf2 signaling pathway,” Drug Des. Devel. Ther., vol. 16, pp. 45–55, 2022, doi: 10.2147/DDDT.S335987.

R. Kaur, S. Mehan, and S. Singh, “Neuroprotective potential of phytochemicals against oxidative stress-induced neurotoxicity: A mechanistic review,” Neurochem. Int., vol. 154, p. 105293, 2022, doi: 10.1016/j.neuint.2022.105293.

S. S. Patel, A. Acharya, R. S. Ray, R. Agrawal, R. Raghuwanshi, and P. Jain, “Cellular uptake and bioavailability of curcumin using novel nano-formulations: A comprehensive review,” J. Drug Deliv. Sci. Technol., p. 102707, 2023, doi: 10.1016/j.jddst.2023.102707.

A. Karthikeyan, N. Senthil, and T. Min, “Curcumin nanoformulations for cancer therapy: Recent advances and future perspectives,” Int. J. Pharm., p. 120221, 2024, doi: 10.1016/j.ijpharm.2023.120221.

Y. Liu, H. Zhang, L. Zhang, X. Zhang, Y. Xie, and W. Zhao, “Genistein ameliorates oxidative stress and inflammation in diabetic nephropathy through activation of Nrf2/HO-1 pathway,” Biomed. Pharmacother., vol. 159, p. 114248, 2023, doi: 10.1016/j.biopha.2023.114248.

X. Chen, N. Gu, C. Xie, and D. Xiang, “Development and validation of an UHPLC–MS/MS method for simultaneous determination of plant-derived anticancer drugs in rat plasma: Application to a pharmacokinetic study,” J. Pharm. Biomed. Anal., vol. 193, p. 113733, 2021, doi: 10.1016/j.jpba.2020.113733.

G. A. Engwa, P. U. Ferdinand, F. N. Nwalo, and M. N. Unachukwu, “Mechanism and health effects of heavy metal toxicity in humans,” in Poisoning in the Modern World. IntechOpen, 2022.

M. Shoji, M. Arakaki, S. Ezaki, T. Yasuhara, and H. Shibata, “Genistein, a soy isoflavone, improves cardiac dysfunction, lowers blood pressure, and mitigates cardiac hypertrophy in diabetic rodent models,” J. Pharmacol. Exp. Ther., vol. 366, no. 1, pp. 10–18, 2018, doi: 10.1124/jpet.118.248708.

M. R. Smith, D. P. Jones, and L. H. Kennedy, “Lead exposure induces mitochondrial dysfunction and increases oxidative stress in the rat brain,” Neurotoxicology, vol. 82, pp. 103–112, 2021, doi: 10.1016/j.neuro.2020.10.003.

C. H. Lee, J. H. Park, and S. H. Kim, “Genistein protects against lead-induced neurotoxicity by regulating oxidative stress and apoptosis in the mouse hippocampus,” Toxicol. Sci., vol. 174, no. 1, pp. 68–77, 2020, doi: 10.1093/toxsci/kfz230.

S. H. Kim, J. H. Park, and C. H. Lee, “Genistein-loaded nanoparticles ameliorate lead-induced hepatic and renal toxicity in mice,” Environ. Toxicol. Pharmacol., vol. 89, p. 103820, 2022, doi: 10.1016/j.etap.2021.103820.

C. H. Park, H. J. Yeo, T. B. Baskar, Y. S. Jeong, M. H. Jeong, W. B. Yoon, and Y. J. Park, “Genistein and daidzein modulate hydrogen peroxide-induced apoptosis through regulation of JNK activation and glutathione levels,” Int. J. Mol. Sci., vol. 20, no. 9, p. 2156, 2019, doi: 10.3390/ijms20092156.

C. H. Lee, J. H. Park, and S. H. Kim, “Genistein-loaded nanoparticles attenuate lead-induced neurotoxicity in mice by modulating oxidative stress, inflammation, and apoptosis,” Oxid. Med. Cell. Longev., vol. 2021, p. 8863789, 2021, doi: 10.1155/2021/8863789.

A. Karimian, Y. Ahmadi, and B. Yousefi, “Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage,” DNA Repair, vol. 42, pp. 63–71, 2016, doi: 10.1016/j.dnarep.2016.04.008.

Y. Zhang, X. Li, D. Zou, W. Liu, J. Yang, N. Zhu, et al., “Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine,” J. Clin. Endocrinol. Metab., vol. 105, no. 6, pp. 2009–2022, 2020, doi: 10.1210/clinem/dgaa078.

S. Bae, J. Choi, Y. Park, and J. Kim, “Lead-induced oxidative stress and its impact on the cell cycle regulation in neuronal cells,” Toxicology, vol. 450, p. 152679, 2021, doi: 10.1016/j.tox.2020.152679.

H. J. Park, H. K. Shin, H. Y. Kim, K. Y. Kim, and M. Choe, “Genistein-rich fermented soy paste improves glucose and lipid metabolism in C57BL/6J mice fed a high-fat diet,” Nutrients, vol. 9, no. 3, p. 278, 2017, doi: 10.3390/nu9030278.

X. Hu, X. Sui, X. Qi, J. Zhang, Z. Yang, Z. Zhou, et al., “Genistein regulates the miR-17-92 cluster to inhibit the proliferation and differentiation of prostate cancer stem/progenitor cells,” Mol. Cell. Endocrinol., vol. 487, pp. 21–33, 2019, doi: 10.1016/j.mce.2019.02.016.

J. Massagué, “TGFβ signaling in the era of precision medicine,” Nat. Rev. Mol. Cell Biol., vol. 22, no. 5, pp. 307–321, 2021, doi: 10.1038/s41580-021-00336-5.

D. Pohlers, J. Brenmoehl, I. Löffler, C. K. Müller, C. Leipner, S. Schultze-Mosgau, and G. Wolf, “TGF-β in tissue fibrosis: From pathophysiology to therapeutic targeting,” BBA – Mol. Basis Dis., vol. 1866, no. 3, p. 165798, 2020, doi: 10.1016/j.bbadis.2019.165798